Skip to content
OpenCapital
Get started

Inhibrx Biosciences, Inc. INBX Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

Nuvation Bio logo
Nuvation BioNUVB
$321K—
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.82M+12.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+385%
Enterprise value$1.42B+982%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s debt issuance cost amortization?
Inhibrx Biosciences, Inc. (INBX) reported debt issuance cost amortization of $732K in Q1 2026.
How has Inhibrx Biosciences, Inc.'s debt issuance cost amortization changed year-over-year?
Inhibrx Biosciences, Inc.'s debt issuance cost amortization increased by 37.3% year-over-year, from $533K to $732K.
What does debt issuance cost amortization mean?
Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).